4-[3-(1h-Imidazol-4-yl)propyl]piperidine | 768358-61-8

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 4-[3-(1h-Imidazol-4-yl)propyl]piperidine
• 英文别名: 4-[3-(1H-imidazol-5-yl)propyl]piperidine
• CAS: 768358-61-8
• 化学式: C₁₁H₁₉N₃
• mdl: MFCD08668976
• 分子量: 193.29
• InChiKey: YPGRNKJNOSUCLY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.727
• 拓扑面积：
  40.7
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• [EN] THERAPEUTIC USES<br/>[FR] UTILISATIONS THÉRAPEUTIQUES
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2013107336A1

  公开（公告）日：2013-07-25

  This invention relates to novel therapeutic uses for compounds which are inverse agonists of the H3 receptor. In particular this invention relates to therapeutic use of these compounds in the treatment of Multiple Sclerosis.

  这项发明涉及与H3受体的逆激动剂相关的新型治疗用途。具体来说，这项发明涉及利用这些化合物在治疗多发性硬化症方面的治疗用途。
• Therapeutic Uses
  申请人：GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED

  公开号：US20150080380A1

  公开（公告）日：2015-03-19

  This invention relates to novel therapeutic uses for compounds which are inverse agonists of the H3 receptor. In particular this invention relates to therapeutic use of these compounds in the treatment of Multiple Sclerosis.

  这项发明涉及对H3受体的反向激动剂的新型治疗用途。具体而言，这项发明涉及这些化合物在治疗多发性硬化症中的治疗用途。
• Pharmaceutical compositions and methods of treating cardiovascular diseases
  申请人：Cardix Therapeutics LLC

  公开号：US10758544B2

  公开（公告）日：2020-09-01

  Provided herein is a pharmaceutical composition comprising two or more compounds, wherein each compound is independently a phosphodiesterase inhibitor, an adenosine receptor antagonist, a calcium channel blocker, a histamine H1-receptor agonist, a histamine H2-receptor agonist, a histamine H3-receptor antagonist, or a β2-adrenoreceptor agonist. Also provided herein is a method of treating, preventing, or ameliorating a cardiovascular disease in a subject, comprising administering to the subject in need thereof two or more compounds, wherein each compound is independently a phosphodiesterase inhibitor, an adenosine receptor antagonist, a calcium channel blocker, a histamine H1-receptor agonist, a histamine H2-receptor agonist, a histamine H3-receptor antagonist, or a β2-adrenoreceptor agonist.

  本文提供了一种药物组合物，该组合物包含两种或两种以上化合物，其中每种化合物都是独立的磷酸二酯酶抑制剂、腺苷受体拮抗剂、钙通道阻滞剂、组胺H1-受体激动剂、组胺H2-受体激动剂、组胺H3-受体拮抗剂或β2-肾上腺素受体激动剂。本文还提供了一种治疗、预防或改善受试者心血管疾病的方法，包括向有需要的受试者施用两种或多种化合物，其中每种化合物都是独立的磷酸二酯酶抑制剂、腺苷受体拮抗剂、钙通道阻滞剂、组胺H1-受体激动剂、组胺H2-受体激动剂、组胺H3-受体拮抗剂或β2-肾上腺素受体激动剂。
• METHODS FOR RESTORATION OF HISTAMINE BALANCE
  申请人：Biohealthonomics Inc.

  公开号：EP2928467A1

  公开（公告）日：2015-10-14
• COMPOSITIONS AND METHODS FOR COMBINATORIAL DRUG DISCOVERY IN NANOLITER DROPLETS
  申请人：The Broad Institute, Inc.

  公开号：EP3694527A1

  公开（公告）日：2020-08-19